Lydia Chougar
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Lydia Chougar has a total of 169 co-authors. Here are the top co-authors by number of shared publications:
David Grabli
Sorbonne Université, Institut du Cerveau - Paris Brain Institute - ICM, AP-HP, CNRS, Inserm, Hôpital de la Pitié Salpêtrière, Department of Neurology, Paris, France
12 shared publicationsStéphane Lehéricy
Sorbonne Université, Institut du Cerveau - Paris Brain Institute - ICM, AP-HP, CNRS, Inserm, Hôpital de la Pitié Salpêtrière, DMU DIAMENT, Department of Neuroradiology, Paris, France
12 shared publicationsNadya Pyatigorskaya
Sorbonne Université, Institut du Cerveau - Paris Brain Institute - ICM, AP-HP, CNRS, Inserm, Hôpital de la Pitié Salpêtrière, DMU DIAMENT, Department of Neuroradiology, Paris, France
8 shared publicationsBertrand Degos
Dynamics and Pathophysiology of Neuronal Networks Team, Center for Interdisciplinary Research in Biology, Collège de France, CNRS, UMR7241/INSERM U1050, Université PSL, Paris, France
7 shared publicationsMarie Vidailhet
Sorbonne Université, Institut du Cerveau - Paris Brain Institute - ICM, AP-HP, CNRS, Inserm, Hôpital de la Pitié Salpêtrière, Department of Neurology, Paris, France
7 shared publications- Jean-Christophe Corvol
Sorbonne Université, Institut du Cerveau, Paris Brain Institute, ICM, Inserm, CNRS, France
6 shared publications
Latest Publications
- Open Access
A Longitudinal Neuromelanin MRI Processing Framework Reduces Measurement Variability and Improves Precision in Parkinson's Disease
Background: Neuromelanin-MRI enables in vivo assessment of the substantia nigra (SN) and locus coeruleus (LC) in individuals with Parkinson's disease (PD), yet longitudinal studies rely on cross-sectional processing that may introduce measurement variability and confound estimates of change over time. Objectives: In this paper, a longitudinal neuromelanin-MRI processing framework is presented that is designed and validated to improve measurement stability and reduce processing-related variability across repeated scans. Methods: Imaging and clinical data from the Quebec Parkinson Network were analyzed in 268 participants (199 PD, 69 controls), including a longitudinal subset of 74 participants (49 PD, 25 controls) scanned approximately one year apart. Validation experiments evaluated slice-by-slice intensity normalization for slice dependent intensity variation, bias field correction for LC signal asymmetry, and the effects of longitudinal registration on measurement stability and PD-control discrimination. Results: Slice-by-slice intensity normalization significantly reduced brainstem intensity variability by 3.6%. A systematic leftward signal asymmetry was observed in the LC and persisted following N4 bias field correction, suggesting a scanner-related effect not captured by conventional bias field modeling. Longitudinal registration reduced annualized change variability by 25-36% for SN_CR and 27-34% for LC_CR metrics in controls, indicating improved within-subject measurement stability. Residual variability was also reduced for contrast-based metrics by up to 28%. Longitudinal registration generally produced larger PD-control effect sizes at baseline and follow-up, particularly for SN volume metrics. However, no significant method x group x time interactions were observed, indicating that estimated longitudinal trajectories did not differ significantly between longitudinal and conventional cross-sectional processing. Conclusions: Longitudinal registration reduced technical variability and improved the precision of NM-MRI measurements. Although it did not significantly enhance detection of longitudinal PD-control differences over the follow-up interval examined here, it provides a more robust framework for longitudinal NM-MRI studies and may improve sensitivity to subtler biological effects in future investigations.
Open AccessA Longitudinal Neuromelanin MRI Processing Framework Reduces Measurement Variability and Improves Precision in Parkinson's Disease
Background: Neuromelanin-MRI enables in vivo assessment of the substantia nigra (SN) and locus coeruleus (LC) in individuals with Parkinson's disease (PD), yet longitudinal studies rely on cross-sectional processing that may introduce measurement variability and confound estimates of change over time. Objectives: In this paper, a longitudinal neuromelanin-MRI processing framework is presented that is designed and validated to improve measurement stability and reduce processing-related variability across repeated scans. Methods: Imaging and clinical data from the Quebec Parkinson Network were analyzed in 268 participants (199 PD, 69 controls), including a longitudinal subset of 74 participants (49 PD, 25 controls) scanned approximately one year apart. Validation experiments evaluated slice-by-slice intensity normalization for slice dependent intensity variation, bias field correction for LC signal asymmetry, and the effects of longitudinal registration on measurement stability and PD-control discrimination. Results: Slice-by-slice intensity normalization significantly reduced brainstem intensity variability by 3.6%. A systematic leftward signal asymmetry was observed in the LC and persisted following N4 bias field correction, suggesting a scanner-related effect not captured by conventional bias field modeling. Longitudinal registration reduced annualized change variability by 25-36% for SN_CR and 27-34% for LC_CR metrics in controls, indicating improved within-subject measurement stability. Residual variability was also reduced for contrast-based metrics by up to 28%. Longitudinal registration generally produced larger PD-control effect sizes at baseline and follow-up, particularly for SN volume metrics. However, no significant method x group x time interactions were observed, indicating that estimated longitudinal trajectories did not differ significantly between longitudinal and conventional cross-sectional processing. Conclusions: Longitudinal registration reduced technical variability and improved the precision of NM-MRI measurements. Although it did not significantly enhance detection of longitudinal PD-control differences over the follow-up interval examined here, it provides a more robust framework for longitudinal NM-MRI studies and may improve sensitivity to subtler biological effects in future investigations.
- 7 April 2026
- Published by Agence Bibliographique de l'Enseignement Supérieur
Apport de l'IRM multimodale pour le diagnostic différentiel des syndromes parkinsoniens
Le syndrome parkinsonien est défini par l'association d'un tremblement de repos, d'une rigidité, d'une bradykinésie et d'une instabilité posturale. La maladie de Parkinson (MP) est la première cause de syndrome parkinsonien d’origine neurodégénérative. Le spectre des syndromes parkinsoniens atypiques fait référence à des pathologies neurodégénératives rares incluant des tauopathies (paralysie supranucléaire progressive - PSP et dégénérescence corticobasale - DCB) et des synucléinopathies (atrophie multisystématisée - AMS, avec ses variantes cérébelleuse - AMS-C et parkinsonienne - AMS-P, et démence à corps de Lewy - DCL). Bien que la précision du diagnostic du syndrome parkinsonien soit améliorée lorsqu'il est posé par des neurologues experts en mouvements anormaux, un diagnostic correct peut être difficile, notamment à la phase précoce de la maladie, avec une incertitude clinique élevée. Or un diagnostic précis est crucial pour évaluer le pronostic, orienter les patients vers des systèmes de soins adéquats et permettre leur inclusion dans des essais thérapeutiques appropriés. Les syndromes parkinsoniens sont caractérisés histologiquement par des lésions cérébrales spécifiques avec une association variable d'atrophie cérébrale dans des régions cérébrales particulières, de modifications de la microstructure tissulaire et de dépôts de fer pathologiques. La dégénérescence des neurones dopaminergiques dans la substance noire pars compacta est la lésion commune à tous les syndromes parkinsoniens neurodégénératifs. Alors que les patients atteints de la maladie de Parkinson ne présentent des anomalies extra-nigrales que dans un nombre limité de petits noyaux du tronc cérébral, les patients atteints de PSP montrent une atteinte plus diffuse, prédominant dans le mésencéphale, le noyau denté et les pédoncules cérébelleux supérieurs et les patients atteints d'AMS sont caractérisés par des dommages affectant particulièrement le putamen postérieur dans l'AMS-P et le pont, les pédoncules cérébelleux moyens et le cervelet dans l'AMS-C. Ces changements peuvent être détectés à l'aide de l’imagerie par résonance magnétique (IRM) multimodale. L'atrophie cérébrale est visible sur les images pondérées en T1, les altérations de la microstructure tissulaire sont détectées à l'aide d'images pondérées en diffusion, les dépôts de fer peuvent être mis en évidence à l'aide de séquences sensibles au fer et la dégénérescence de la substance noire est visible grâce de l'imagerie sensible à la neuromélanine. L'objectif de ma thèse est d'évaluer la contribution de l'IRM multimodale pour le diagnostic différentiel des syndromes parkinsoniens. Nous avons montré qu'une approche de classification diagnostique basée sur des techniques d'apprentissage automatique en combinaison avec des mesures de volumétrie, de diffusion et de relaxation R2* dans diverses régions du cerveau permettait de discriminer avec précision les sujets à un stade précoce de syndrome parkinsonien. En utilisant l'imagerie sensible à la neuromélanine, nous avons détecté la dégénérescence de la substance noire et du locus coeruleus dans les syndromes parkinsoniens. Nous avons également constaté que le pattern de la dégénérescence nigrale différait entre les synucléinopathies et les tauopathies. Ces résultats pourraient aider à affiner le diagnostic différentiel du syndrome parkinsonien dans un contexte clinique.
- 7 April 2026
- Published by Agence Bibliographique de l'Enseignement Supérieur
Apport de l'IRM multimodale pour le diagnostic différentiel des syndromes parkinsoniens
Le syndrome parkinsonien est défini par l'association d'un tremblement de repos, d'une rigidité, d'une bradykinésie et d'une instabilité posturale. La maladie de Parkinson (MP) est la première cause de syndrome parkinsonien d’origine neurodégénérative. Le spectre des syndromes parkinsoniens atypiques fait référence à des pathologies neurodégénératives rares incluant des tauopathies (paralysie supranucléaire progressive - PSP et dégénérescence corticobasale - DCB) et des synucléinopathies (atrophie multisystématisée - AMS, avec ses variantes cérébelleuse - AMS-C et parkinsonienne - AMS-P, et démence à corps de Lewy - DCL). Bien que la précision du diagnostic du syndrome parkinsonien soit améliorée lorsqu'il est posé par des neurologues experts en mouvements anormaux, un diagnostic correct peut être difficile, notamment à la phase précoce de la maladie, avec une incertitude clinique élevée. Or un diagnostic précis est crucial pour évaluer le pronostic, orienter les patients vers des systèmes de soins adéquats et permettre leur inclusion dans des essais thérapeutiques appropriés. Les syndromes parkinsoniens sont caractérisés histologiquement par des lésions cérébrales spécifiques avec une association variable d'atrophie cérébrale dans des régions cérébrales particulières, de modifications de la microstructure tissulaire et de dépôts de fer pathologiques. La dégénérescence des neurones dopaminergiques dans la substance noire pars compacta est la lésion commune à tous les syndromes parkinsoniens neurodégénératifs. Alors que les patients atteints de la maladie de Parkinson ne présentent des anomalies extra-nigrales que dans un nombre limité de petits noyaux du tronc cérébral, les patients atteints de PSP montrent une atteinte plus diffuse, prédominant dans le mésencéphale, le noyau denté et les pédoncules cérébelleux supérieurs et les patients atteints d'AMS sont caractérisés par des dommages affectant particulièrement le putamen postérieur dans l'AMS-P et le pont, les pédoncules cérébelleux moyens et le cervelet dans l'AMS-C. Ces changements peuvent être détectés à l'aide de l’imagerie par résonance magnétique (IRM) multimodale. L'atrophie cérébrale est visible sur les images pondérées en T1, les altérations de la microstructure tissulaire sont détectées à l'aide d'images pondérées en diffusion, les dépôts de fer peuvent être mis en évidence à l'aide de séquences sensibles au fer et la dégénérescence de la substance noire est visible grâce de l'imagerie sensible à la neuromélanine. L'objectif de ma thèse est d'évaluer la contribution de l'IRM multimodale pour le diagnostic différentiel des syndromes parkinsoniens. Nous avons montré qu'une approche de classification diagnostique basée sur des techniques d'apprentissage automatique en combinaison avec des mesures de volumétrie, de diffusion et de relaxation R2* dans diverses régions du cerveau permettait de discriminer avec précision les sujets à un stade précoce de syndrome parkinsonien. En utilisant l'imagerie sensible à la neuromélanine, nous avons détecté la dégénérescence de la substance noire et du locus coeruleus dans les syndromes parkinsoniens. Nous avons également constaté que le pattern de la dégénérescence nigrale différait entre les synucléinopathies et les tauopathies. Ces résultats pourraient aider à affiner le diagnostic différentiel du syndrome parkinsonien dans un contexte clinique.
- Open Access
- 26 December 2025
- Published by Springer Nature in npj Parkinson's Disease
- Vol. 12 (1)
MRI-derived atrophy in multiple system atrophy aligns with mitochondrial and glial gene expression patterns
Oligodendroglial pathology is a hallmark of multiple system atrophy (MSA), yet it remains unclear whether MRI-detected atrophy reflects underlying biological mechanisms. This study investigated whether regional atrophy aligns with gene expression and neurotransmitter systems. We recruited 65 MSA patients and derived brain atrophy measures from T1-weighted MRIs. Using postmortem data from the Allen Human Brain Atlas, partial least squares (PLS) regression identified gene expression components associated with brain atrophy. Gene enrichment analyses explored biological processes, and annotation mapping identified neurotransmitter systems matching atrophy patterns. Specificity was tested against 57 patients with Parkinson’s disease. Atrophy primarily affected the cerebellar white matter, pons, putamen, olive, and substantia nigra. PLS revealed two latent variables explaining 27.5% of the covariance. Atrophic regions overexpressed genes linked to mitochondrial function and oligodendrocytes, showing patterns distinct from Parkinson’s disease. These regions also exhibited lower serotonin and GABA levels, and higher acetylcholine and noradrenaline receptor densities. MRI-derived atrophy in MSA is biologically grounded and may inform future therapeutic studies.
- 26 December 2025
- Published by Springer Nature in npj Parkinson's Disease
- Vol. 12 (1)
Open AccessMRI-derived atrophy in multiple system atrophy aligns with mitochondrial and glial gene expression patterns
Oligodendroglial pathology is a hallmark of multiple system atrophy (MSA), yet it remains unclear whether MRI-detected atrophy reflects underlying biological mechanisms. This study investigated whether regional atrophy aligns with gene expression and neurotransmitter systems. We recruited 65 MSA patients and derived brain atrophy measures from T1-weighted MRIs. Using postmortem data from the Allen Human Brain Atlas, partial least squares (PLS) regression identified gene expression components associated with brain atrophy. Gene enrichment analyses explored biological processes, and annotation mapping identified neurotransmitter systems matching atrophy patterns. Specificity was tested against 57 patients with Parkinson’s disease. Atrophy primarily affected the cerebellar white matter, pons, putamen, olive, and substantia nigra. PLS revealed two latent variables explaining 27.5% of the covariance. Atrophic regions overexpressed genes linked to mitochondrial function and oligodendrocytes, showing patterns distinct from Parkinson’s disease. These regions also exhibited lower serotonin and GABA levels, and higher acetylcholine and noradrenaline receptor densities. MRI-derived atrophy in MSA is biologically grounded and may inform future therapeutic studies.
- 4 December 2025
- Published by Wiley in Movement Disorders
- Vol. 41 (1) , 275-276
Reply to: Deep Learning to Differentiate Parkinsonian Syndromes: From Proof of Concept to Clinical Trust
- 4 December 2025
- Published by Wiley in Movement Disorders
- Vol. 41 (1) , 275-276
Reply to: Deep Learning to Differentiate Parkinsonian Syndromes: From Proof of Concept to Clinical Trust
- Open Access
- 24 July 2025
- Published by Wiley in Movement Disorders
- Vol. 40 (10) , 2139-2148
Deep Learning to Differentiate Parkinsonian Syndromes Using Multimodal Magnetic Resonance Imaging : A Proof‐of‐Concept Study
Background: The differentiation between multiple system atrophy (MSA) and Parkinson's disease (PD) based on clinical diagnostic criteria can be challenging, especially at an early stage. Leveraging deep learning methods and magnetic resonance imaging (MRI) data has shown great potential in aiding automatic diagnosis. Objective: The aim was to determine the feasibility of a three‐dimensional convolutional neural network (3D CNN)–based approach using multimodal, multicentric MRI data for differentiating MSA and its variants from PD. Methods: MRI data were retrospectively collected from three MSA French reference centers. We computed quantitative maps of gray matter density (GD) from a T1‐weighted sequence and mean diffusivity (MD) from diffusion tensor imaging. These maps were used as input to a 3D CNN, either individually (“monomodal,” “GD” or “MD”) or in combination (“bimodal,” “GD‐MD”). Classification tasks included the differentiation of PD and MSA patients. Model interpretability was investigated by analyzing misclassified patients and providing a visual interpretation of the most activated regions in CNN predictions. Results: The study population included 92 patients with MSA (50 with MSA‐P, parkinsonian variant; 33 with MSA‐C, cerebellar variant; 9 with MSA‐PC, mixed variant) and 64 with PD. The best accuracies were obtained for the PD/MSA (0.88 ± 0.03 with GD‐MD), PD/MSA‐C&PC (0.84 ± 0.08 with MD), and PD/MSA‐P (0.78 ± 0.09 with GD) tasks. Patients misclassified by the CNN exhibited fewer and milder image alterations, as found using an image‐based z score analysis. Activation maps highlighted regions involved in MSA pathophysiology, namely the putamen and cerebellum. Conclusions: Our findings hold promise for developing an efficient, MRI‐based, and user‐independent diagnostic tool suitable for differentiating parkinsonian syndromes in clinical practice. © 2025 The Author(s). Movement Disorders published by Wiley Periodicals LLC on behalf of International Parkinson and Movement Disorder Society.
- 24 July 2025
- Published by Wiley in Movement Disorders
- Vol. 40 (10) , 2139-2148
Open AccessDeep Learning to Differentiate Parkinsonian Syndromes Using Multimodal Magnetic Resonance Imaging : A Proof‐of‐Concept Study
Background: The differentiation between multiple system atrophy (MSA) and Parkinson's disease (PD) based on clinical diagnostic criteria can be challenging, especially at an early stage. Leveraging deep learning methods and magnetic resonance imaging (MRI) data has shown great potential in aiding automatic diagnosis. Objective: The aim was to determine the feasibility of a three‐dimensional convolutional neural network (3D CNN)–based approach using multimodal, multicentric MRI data for differentiating MSA and its variants from PD. Methods: MRI data were retrospectively collected from three MSA French reference centers. We computed quantitative maps of gray matter density (GD) from a T1‐weighted sequence and mean diffusivity (MD) from diffusion tensor imaging. These maps were used as input to a 3D CNN, either individually (“monomodal,” “GD” or “MD”) or in combination (“bimodal,” “GD‐MD”). Classification tasks included the differentiation of PD and MSA patients. Model interpretability was investigated by analyzing misclassified patients and providing a visual interpretation of the most activated regions in CNN predictions. Results: The study population included 92 patients with MSA (50 with MSA‐P, parkinsonian variant; 33 with MSA‐C, cerebellar variant; 9 with MSA‐PC, mixed variant) and 64 with PD. The best accuracies were obtained for the PD/MSA (0.88 ± 0.03 with GD‐MD), PD/MSA‐C&PC (0.84 ± 0.08 with MD), and PD/MSA‐P (0.78 ± 0.09 with GD) tasks. Patients misclassified by the CNN exhibited fewer and milder image alterations, as found using an image‐based z score analysis. Activation maps highlighted regions involved in MSA pathophysiology, namely the putamen and cerebellum. Conclusions: Our findings hold promise for developing an efficient, MRI‐based, and user‐independent diagnostic tool suitable for differentiating parkinsonian syndromes in clinical practice. © 2025 The Author(s). Movement Disorders published by Wiley Periodicals LLC on behalf of International Parkinson and Movement Disorder Society.
- Open Access
- 27 June 2025
- Published by Wiley in European Journal of Neurology
- Vol. 32 (7)
Longitudinal PET and MRI Evaluation in Late Onset Rasmussen Encephalitis: A Series of Three Cases
Background: Rasmussen's encephalitis (RE) is a rare, chronic, neurological disorder characterized by progressive focal epilepsy and hemispheric atrophy. Late‐onset RE poses diagnostic challenges due to atypical clinical features and nonspecific early MRI findings.Methods: This case series underscores the value of [18F]FDG PET in detecting unihemispheric hypometabolism and crossed cerebellar diaschisis at diagnosis, before MRI changes appear.Results: During follow‐up, PET identified active disease through hypermetabolic foci or pseudo‐normalized metabolism, indicative of subclinical seizures, while stable hypometabolism signaled quiescence.Conclusion: Combining PET with MRI enhances diagnostic accuracy and guides treatment decisions in managing RE.
- 27 June 2025
- Published by Wiley in European Journal of Neurology
- Vol. 32 (7)
Open AccessLongitudinal PET and MRI Evaluation in Late Onset Rasmussen Encephalitis: A Series of Three Cases
Background: Rasmussen's encephalitis (RE) is a rare, chronic, neurological disorder characterized by progressive focal epilepsy and hemispheric atrophy. Late‐onset RE poses diagnostic challenges due to atypical clinical features and nonspecific early MRI findings.Methods: This case series underscores the value of [18F]FDG PET in detecting unihemispheric hypometabolism and crossed cerebellar diaschisis at diagnosis, before MRI changes appear.Results: During follow‐up, PET identified active disease through hypermetabolic foci or pseudo‐normalized metabolism, indicative of subclinical seizures, while stable hypometabolism signaled quiescence.Conclusion: Combining PET with MRI enhances diagnostic accuracy and guides treatment decisions in managing RE.
- 2 May 2025
- Published by Elsevier in Medical Image Analysis
- Vol. 103, 103617
Automatic quality control of brain 3D FLAIR MRIs for a clinical data warehouse
- 2 May 2025
- Published by Elsevier in Medical Image Analysis
- Vol. 103, 103617
Automatic quality control of brain 3D FLAIR MRIs for a clinical data warehouse
- Open Access
Atrophy in multiple system atrophy relates to mitochondrial and oligodendrocytic processes
Objective To investigate the gene expression and neurobiological underpinnings of brain atrophy in multiple system atrophy (MSA) using imaging transcriptomics and PET-based molecular annotation. Methods We derived brain atrophy measurements from the T1-weighted MRI scans of 65 patients with MSA and 181 age- and sex-matched healthy controls. Using postmortem data from the Allen Human Brain Atlas, partial least square (PLS) regression was used to identify gene expression components associated with atrophy. Gene enrichment analyses were performed to investigate the biological processes with enriched genes in regions showing atrophy. Annotation mapping was used to identify the neurochemical systems whose density maps matched atrophy in MSA. Results Atrophy in MSA was found to primarily affect deep brain regions, including the cerebellar white matter, pons, putamen, olive nuclei, and substantia nigra. PLS regression on deep brain region atrophy identified two gene expression latent variables, explaining 27.5% of the covariance. Regions with greater atrophy overexpressed genes related to the mitochondrial respiratory chain, particularly proton transmembrane transport and complex I assembly. In addition, cell type analysis revealed that regions with atrophy overexpressed genes related to oligodendrocytes. These patterns were distinct from those found in Parkinson’s disease. Atrophic regions in MSA also displayed less serotonin and GABA receptors and more acetylcholine and noradrenaline receptors. Interpretation Regions showing atrophy in MSA show specific features, namely overexpression of genes related to mitochondrial function and oligodendrocytes and distinct neurochemical patterns. This study highlights some of the biological and neurochemical mechanisms underlying selective vulnerability of brain regions in MSA.
Open AccessAtrophy in multiple system atrophy relates to mitochondrial and oligodendrocytic processes
Objective To investigate the gene expression and neurobiological underpinnings of brain atrophy in multiple system atrophy (MSA) using imaging transcriptomics and PET-based molecular annotation. Methods We derived brain atrophy measurements from the T1-weighted MRI scans of 65 patients with MSA and 181 age- and sex-matched healthy controls. Using postmortem data from the Allen Human Brain Atlas, partial least square (PLS) regression was used to identify gene expression components associated with atrophy. Gene enrichment analyses were performed to investigate the biological processes with enriched genes in regions showing atrophy. Annotation mapping was used to identify the neurochemical systems whose density maps matched atrophy in MSA. Results Atrophy in MSA was found to primarily affect deep brain regions, including the cerebellar white matter, pons, putamen, olive nuclei, and substantia nigra. PLS regression on deep brain region atrophy identified two gene expression latent variables, explaining 27.5% of the covariance. Regions with greater atrophy overexpressed genes related to the mitochondrial respiratory chain, particularly proton transmembrane transport and complex I assembly. In addition, cell type analysis revealed that regions with atrophy overexpressed genes related to oligodendrocytes. These patterns were distinct from those found in Parkinson’s disease. Atrophic regions in MSA also displayed less serotonin and GABA receptors and more acetylcholine and noradrenaline receptors. Interpretation Regions showing atrophy in MSA show specific features, namely overexpression of genes related to mitochondrial function and oligodendrocytes and distinct neurochemical patterns. This study highlights some of the biological and neurochemical mechanisms underlying selective vulnerability of brain regions in MSA.
- Open Access
- 5 January 2025
- Published by Wiley in European Journal of Neurology
- Vol. 32 (1) , e70035
Substantia nigra degeneration in spinocerebellar ataxia 2 and 7 using neuromelanin‐sensitive imaging
Objective: Spinocerebellar ataxias (SCA) are neurodegenerative diseases with widespread lesions across the central nervous system. Ataxia and spasticity are usually predominant, but patients may also present with parkinsonism. We aimed to characterize substantia nigra pars compacta (SNc) degeneration in SCA2 and 7 using neuromelanin‐sensitive imaging.Methods: Ataxic and preataxic expansion carriers with SCA2 (n=15) and SCA7 (n=15) and healthy controls (n=10) were prospectively recruited. Volume and signal‐to‐noise ratio (SNR) values of the SNc were extracted from neuromelanin‐sensitive images. ROC curves were used to determine the metrics that best differentiated SCA participants. Correlations between imaging measurements, clinical variables, and plasma neurofilaments light chain (NfL) levels were investigated.Results: SCA2 participants had lower SNR values in the SNc than controls (110.2 ± 1.3 versus 113.2 ± 1.4; p < 0.001) and those with SCA7 (112.5 ± 2.1; p < 0.01). SNR in SCA7 participants and controls did not differ. In ataxic patients, SNc volumes were lower in SCA2 (0.13 ± 0.04; p = 0.06) and SCA7 (0.10 ± 0.03, p = 0.02) patients compared to controls (0.17 ± 0.04). Signal decrease was detected at the preataxic stage in SCA2, but not in SCA7. SCA2 participants showed prominent involvement of the associative and limbic nigral territories. SNR discriminated ataxic and preataxic SCA2 participants from controls (AUC ≥0.94). SNc volume differentiated ataxic SCA7 participants from controls (AUC = 1), but not preataxic ones. In SCA7, correlations were observed between SNc volume and time to onset, CAG repeats, clinical severity scores, and NfL.Conclusions: Neuromelanin‐sensitive imaging provides biomarkers of nigral degeneration in SCAs, detectable from the preataxic stage in SCA2, which could potentially serve as outcome measures in clinical trials.
- 5 January 2025
- Published by Wiley in European Journal of Neurology
- Vol. 32 (1) , e70035
Open AccessSubstantia nigra degeneration in spinocerebellar ataxia 2 and 7 using neuromelanin‐sensitive imaging
Objective: Spinocerebellar ataxias (SCA) are neurodegenerative diseases with widespread lesions across the central nervous system. Ataxia and spasticity are usually predominant, but patients may also present with parkinsonism. We aimed to characterize substantia nigra pars compacta (SNc) degeneration in SCA2 and 7 using neuromelanin‐sensitive imaging.Methods: Ataxic and preataxic expansion carriers with SCA2 (n=15) and SCA7 (n=15) and healthy controls (n=10) were prospectively recruited. Volume and signal‐to‐noise ratio (SNR) values of the SNc were extracted from neuromelanin‐sensitive images. ROC curves were used to determine the metrics that best differentiated SCA participants. Correlations between imaging measurements, clinical variables, and plasma neurofilaments light chain (NfL) levels were investigated.Results: SCA2 participants had lower SNR values in the SNc than controls (110.2 ± 1.3 versus 113.2 ± 1.4; p < 0.001) and those with SCA7 (112.5 ± 2.1; p < 0.01). SNR in SCA7 participants and controls did not differ. In ataxic patients, SNc volumes were lower in SCA2 (0.13 ± 0.04; p = 0.06) and SCA7 (0.10 ± 0.03, p = 0.02) patients compared to controls (0.17 ± 0.04). Signal decrease was detected at the preataxic stage in SCA2, but not in SCA7. SCA2 participants showed prominent involvement of the associative and limbic nigral territories. SNR discriminated ataxic and preataxic SCA2 participants from controls (AUC ≥0.94). SNc volume differentiated ataxic SCA7 participants from controls (AUC = 1), but not preataxic ones. In SCA7, correlations were observed between SNc volume and time to onset, CAG repeats, clinical severity scores, and NfL.Conclusions: Neuromelanin‐sensitive imaging provides biomarkers of nigral degeneration in SCAs, detectable from the preataxic stage in SCA2, which could potentially serve as outcome measures in clinical trials.
- Open Access
- 14 March 2024
- Published by Wiley in Movement Disorders
- Vol. 39 (5) , 825-835
Contribution of MRI for the Early Diagnosis of Parkinsonism in Patients with Diagnostic Uncertainty
Background: International clinical criteria are the reference for the diagnosis of degenerative parkinsonism in clinical research, but they may lack sensitivity and specificity in the early stages.Objectives: To determine whether magnetic resonance imaging (MRI) analysis, through visual reading or machine‐learning approaches, improves diagnostic accuracy compared with clinical diagnosis at an early stage in patients referred for suspected degenerative parkinsonism.Materials: Patients with initial diagnostic uncertainty between Parkinson's disease (PD), progressive supranuclear palsy (PSP), and multisystem atrophy (MSA), with brain MRI performed at the initial visit (V1) and available 2‐year follow‐up (V2), were included. We evaluated the accuracy of the diagnosis established based on: (1) the international clinical diagnostic criteria for PD, PSP, and MSA at V1 (“Clin1”); (2) MRI visual reading blinded to the clinical diagnosis (“MRI”); (3) both MRI visual reading and clinical criteria at V1 (“MRI and Clin1”), and (4) a machine‐learning algorithm (“Algorithm”). The gold standard diagnosis was established by expert consensus after a 2‐year follow‐up.Results: We recruited 113 patients (53 with PD, 31 with PSP, and 29 with MSA). Considering the whole population, compared with clinical criteria at the initial visit (“Clin1”: balanced accuracy, 66.2%), MRI visual reading showed a diagnostic gain of 14.3% (“MRI”: 80.5%; P = 0.01), increasing to 19.2% when combined with the clinical diagnosis at the initial visit (“MRI and Clin1”: 85.4%; P < 0.0001). The algorithm achieved a diagnostic gain of 9.9% (“Algorithm”: 76.1%; P = 0.08).Conclusion: Our study shows the use of MRI analysis, whether by visual reading or machine‐learning methods, for early differentiation of parkinsonism. © 2024 The Authors. Movement Disorders published by Wiley Periodicals LLC on behalf of International Parkinson and Movement Disorder Society.
- 14 March 2024
- Published by Wiley in Movement Disorders
- Vol. 39 (5) , 825-835
Open AccessContribution of MRI for the Early Diagnosis of Parkinsonism in Patients with Diagnostic Uncertainty
Background: International clinical criteria are the reference for the diagnosis of degenerative parkinsonism in clinical research, but they may lack sensitivity and specificity in the early stages.Objectives: To determine whether magnetic resonance imaging (MRI) analysis, through visual reading or machine‐learning approaches, improves diagnostic accuracy compared with clinical diagnosis at an early stage in patients referred for suspected degenerative parkinsonism.Materials: Patients with initial diagnostic uncertainty between Parkinson's disease (PD), progressive supranuclear palsy (PSP), and multisystem atrophy (MSA), with brain MRI performed at the initial visit (V1) and available 2‐year follow‐up (V2), were included. We evaluated the accuracy of the diagnosis established based on: (1) the international clinical diagnostic criteria for PD, PSP, and MSA at V1 (“Clin1”); (2) MRI visual reading blinded to the clinical diagnosis (“MRI”); (3) both MRI visual reading and clinical criteria at V1 (“MRI and Clin1”), and (4) a machine‐learning algorithm (“Algorithm”). The gold standard diagnosis was established by expert consensus after a 2‐year follow‐up.Results: We recruited 113 patients (53 with PD, 31 with PSP, and 29 with MSA). Considering the whole population, compared with clinical criteria at the initial visit (“Clin1”: balanced accuracy, 66.2%), MRI visual reading showed a diagnostic gain of 14.3% (“MRI”: 80.5%; P = 0.01), increasing to 19.2% when combined with the clinical diagnosis at the initial visit (“MRI and Clin1”: 85.4%; P < 0.0001). The algorithm achieved a diagnostic gain of 9.9% (“Algorithm”: 76.1%; P = 0.08).Conclusion: Our study shows the use of MRI analysis, whether by visual reading or machine‐learning methods, for early differentiation of parkinsonism. © 2024 The Authors. Movement Disorders published by Wiley Periodicals LLC on behalf of International Parkinson and Movement Disorder Society.